程序性死亡受体1（PD1）配体功能：头颈部鳞状细胞癌（HNSCC）患者对抗PD1治疗反应的生物标志物
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC.
作者信息
Kaufman Bar, Taha Tarek, Abramov Orli, Zohar Yaniv, Mhameed Kamel, Cohen Ofir, Porgador Angel, Elkabets Moshe, Billan Salem
机构信息
The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.
The Joseph Fishman Oncology Center, Rambam Health Care Campus, Haifa, Affiliated to the Rappaport Faculty of Medicine, Israel Institute of Technology-Technion, Haifa, 3109601, Israel.
出版信息
NPJ Precis Oncol. 2024 Jun 3;8(1):126. doi: 10.1038/s41698-024-00620-y.
Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands' functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.
针对PD-1/PD-L1通路的疗法已经改变了头颈部鳞状细胞癌（HNSCC）的治疗方式。然而，预测对抗PD-1疗法的反应仍然是一项临床挑战。本研究评估了29例HNSCC患者中PD-1配体的功能结合情况，并将其与标准的PD-L1联合阳性评分（CPS）进行比较。对PD-1配体功能的评估提高了目前预测HNSCC患者对抗PD-1疗法反应的能力。
Zotero 插件